Objectives: Head and neck squamous cell carcinoma (HNSCC) is characterized by high mortality and low survival rates. As an epidermal growth factor receptor (EGFR) inhibitor, Erlotinib has been approved for treatment of various tumours. PF-03084014 is a selective inhibitor of Notch1 signalling. This study aimed to explore new approaches for simultaneously targeting EGFR and Notch1 signalling to attenuate tumour growth and improve survival.
Recently, EGFR inhibition was reported to promote epithelial-tomesenchymal transition (EMT), 11 increase the number of cancerassociated fibroblasts 12 and activate Notch expression. 13 Moreover, Erlotinib has demonstrated poor clinical response rates (5%-15%) and disappointing results in clinical trials for HNSCC. 14 Another study reported the enrichment of stem cell-like cancer cells in EGFR-mutant lung cancer cell lines treated with Erlotinib through EGFR-dependent activation of Notch3. 13 Thus, development of optimal combinatorial therapies to eliminate the resistance to Erlotinib is important.
Notch1 is overexpressed in HNSCC. 2 Previously, our research revealed common mutations in the Notch1 gene in HNSCC, which is observed in 43% of Asian patients. A considerable number of these mutations can activate Notch1 pathway. 15 Notch1 is consecutively cleaved by ADAM metalloproteinase and a presenilin/ γ-secretase complex, resulting in the release of Notch1 intracellular domain (NICD). [16] [17] [18] Chemical inhibitors of γ-secretase can suppress proteolysis-dependent activation of Notch1. 16 PF-03084014 is a potent and selective inhibitor of γ-secretase activity and is generally safe and well tolerated by oral administration at doses equal to or less than 150 mg of BID in phase I clinical trials. 19 In addition, PF-03084014 displays a dose-dependent pharmacokinetic profile. 20, 21 Preliminary evidence of antitumour efficacy is observed in patients with advanced solid malignancies, including thyroid cancer and desmoid tumours. 22 In a preclinical model of T-cell acute lymphoblastic leukaemia (T-ALL),
PF-03084014 has induced cell growth arrest by hindering cell-cycle progression and enhancing apoptosis. 23 In breast cancer cell line xenografts, PF-03084014 alters endothelial cell tube formation and exhibits anti-tumoural and anti-angiogenic efficacy. 24 However, no associated published articles have reported the efficacy of PF-03084014 in HNSCC in vivo or in vitro.
Crosstalk between Notch1 and EGFR signalling in cell proliferation and cancer expression has been observed in genomics. [25] [26] [27] Notch1-dependent regulation of EGFR has been described in several types of cancers. Thus, we sought to determine how 2 signalling pathways interplay by assessing the effects of dual-pathway inhibition. We found that none of the pathway inhibition is functional for cell survival in HNSCC. Dual inhibition using Erlotinib and PF-03084014 resulted in a marked decrease in cell proliferation, an increase in cell death, and an induction of apoptosis in a xenograft model. One mechanism has been found in our study that PF-03084014 alone could activate the PI3K-AKT pathway, the downstream of EGFR signalling.
Meanwhile, Erlotinib alone could activate Notch1 downstream translation. Combined treatment of PF-03084014 and Erlotinib reversed PF-03084014-or Erlotinib-induced signalling activation. These results suggest a correlation between the EGFR and Notch1 signalling pathways in HNSCC and a rationale for combined blockade. were purchased from Selleck (Selleck Chem, Houston). All drugs were dissolved in dimethyl sulfoxide (DMSO), which was also used for treatment controls.
| MATERIALS AND METHODS

| Cell culture and inhibitors
| HNSCC xenograft tumour model and therapeutic inhibitors gavaging
All animal studies were approved and supervised by Animal Care and Use Committee of Nanjing Medical University, and all procedures were performed in accordance with institutional animal welfare guidelines of Nanjing Medical University. All mice were maintained in spe- gents were mixed in food and administered daily by oral gavage for a period of 21 days (7-day gavage + 7-day break+7-day gavage).
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Tumour growth was determined by measuring the size of the tumours thrice per week, and the tumour volume was calculated using the fol- 
| Western blot analysis
Total protein was lysed for 30 minutes using lysis buffer (Beyotime, Shanghai, China) containing protease inhibitor cocktail and phosphatase inhibitor cocktail. All proteins (10 μg) were separated using SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, MA), which were then blocked with 5% BSA at room tempera- 
| Immunofluorescence staining
Briefly, HN6 cells were seeded onto sterile glass-coverslips in 24 
| Immunohistochemistry
Tumour specimens were fixed in 10% neutral buffered formalin for 24 hours followed by standard tissue processing and embedding.
Sections were cut at 4 μm and dried overnight at 37°C onto microscope slides. The tissue sections were stained with primary antibodies against Notch1 (#3608, CST), p-EGFR (#3777, CST) and Ki67
(ab92742, Abcam) overnight following secondary antibody incubation for 30 minutes. All of the sections were counterstained using haematoxylin, dehydrated, cleared and mounted before examination using a microscope (DM4000B, Leica, Germany).
| Colony-formation assays
HN6, CAL27 and UMSCC38 cells were plated at a density of 1000 cells per well in 35 mm culture plates containing 3 mL of complete medium followed by incubation at 37°C and 5% CO 2 . By given inhibitors or DMSO once a day, the cells were cultured for 10 days. Cell colonies were stained with 0.005% crystal violet and analysed by microscopy. Thereafter, the filters were fixed and stained with crystal violet and subsequently washed to collect the staining solution.
| Cell invasion assays
| Cell counting kit-8 (CCK-8) experiments
Cells were seeded in 96-well microplates at a density of 2 × 10 3 cells per well. Cells were incubated in new medium containing 10% CCK-8 reaction solution (DOJINDO, Japan). After incubation for 2 hour, the absorbance was measured on a spectrophotometer microplate reader (Multiskan MK3, Thermo) at a wavelength of 450 nm according to the manufacturer's instructions. Five independent experiments were performed.
| Flow cytometry
To and observed using a microscope (DM4000B, Leica, Germany).
| TUNEL assays
| Statistical analysis
All experiments were repeated at least 3 times. Each data point represents the mean ± SD of data from 3 independent trials. Student's t test was used to evaluate the statistical significance of the results. All P-values represented 2-sided tests of statistical significance. All analyses were performed using the SPSS 16.0 software package (*P < .05, **P < .01, ***P < .001). We then investigated whether dual inhibition showed any additive effects on cell proliferation. We compared the effects of combined Additionally, to confirm the inhibitory effects on the long-term growth potential, colony-formation assays were performed in the 3 HNSCC cell lines. As displayed in Figure S1 , after treatment of PF-03084014 or Erlotinib individually, both the 2 inhibitors had limited effects on cell growth. However, a dramatic suppression of cell growth was observed after combined treatment in these cell lines.
| RESULTS
| Combined treatment of Erlotinib and PF-03084014 resulted in synergistic reduced cell proliferation in HNSCC
| Combined treatment reversed the enhanced invasion induced by Erlotinib treatment in HN6 and CAL27 cells
More recently, EGFR inhibition was reported to promote EMT, increasing the number of cancer-associated fibroblasts, and activate Notch expression in NSCLC cell lines. showed that although we did not observe an enhancement in invasion by single treatment (data not shown), a deduction of invasive ability was detected by dual-pathway inhibitions ( Figure 2D ).
| Combined inhibition resulted in cell apoptosis in HNSCC
To determine the function of Erlotinib and PF-03084014 in cell cycle,
we performed Flow cytometry analysis in CAL27 cells after treated with Erlotinib ( Figure 3A) or PF-03084014 ( Figure 3B ) for 3 days. The results revealed that Erlotinib predominantly induced cell-cycle arrest in the G1 phase, whereas PF-03084014 slightly increased the number in the G2 phase ( Figure 3A and B) . Moreover, combined inhibition resulted in growth arrest characterized by an increase of cells in the G1 phase and a decrease in the G2 phase ( Figure 3C ). Similar effects were observed in HN6 and UMSCC38 cell lines (data not shown).
We then performed Annexin V-FITC/propidium iodide (PI) staining to detect the apoptosis rates. We found that when CAL27 cells were treated with both PF-03084014 and Erlotinib for 3 days, early apoptosis was substantially increased, whereas single-drug treatment had minimal effects ( Figure 3D ). Terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-dUTP nick-end labelling (TUNEL assay) was also utilized to investigate cell apoptosis. 29 After 3 days of combined treatment, cells exhibited enhanced positive TUNEL staining, compared with the cells treated with singe drugs ( Figure 3E ).
Activation of Caspase-3 in different cell types has been reported to be required for cell death. 30 As a result, we examined cleaved Caspase-3 by immunofluorescence in HN6 cells after treatment. As anticipated, the expression of Cleaved Caspase-3 in cells after combined treatment was much higher than the cells with single treatment, indicating the induction of early apoptosis induced by combined treatment of PF-03084014
and Erlotinib ( Figure 3F ). Apart from the caspase family, as a member of the pro-survival subfamily, Bcl-2 also plays a pivotal role in cancer cell survival. 31 The results of Western blot analysis also verified enhanced apoptosis as both Cleaved Caspase-3 and Bcl-2 protein expression was increased induced by combined therapy ( Figure 3G ).
| Combined treatment induced tumour growth reduction and synthetic lethality in vivo
To further investigate the potential efficacy of combined inhibition of the 2 pathways, we performed a preclinical therapeutic drug trial in vivo using a xenograft tumour model of CAL27 cells in mice. Erlotinib and/or PF-03084014 treatment was performed as outlined in the general scheme 20 in Figure 4A . After 3 weeks of treatment, all mice were killed and the tumours dissected from mice were presented in To assess the proliferative ability of cells in the 4 groups, the Ki67 Tumour tissues were further analysed by IHC to detect the efficacy of the inhibitors. In the control group gavaged with DMSO, both
Notch1 and p-EGFR were overexpressed (Figure 4Fa-b) . Nevertheless, we found that although Erlotinib treatment alone efficiently inhibited p-EGFR expression, it induced NICD translocation into the nucleus (Figure 4Fc-d) . In addition, PF-03084014 treatment alone decreased Notch1 membranous expression and NICD translocation (Figure 4Fe ).
By comparison, combination treatment decreased p-EGFR and
Notch1 expression compared with the other groups (Figure 4Fg-h ). Figure 2Fg . Cell numbers were counted in 3 independent visions. Scale bar = 50 μm. (G) Immunoblot analysis using cleaved Caspase-3 and Bcl-2 antibodies after treatment in CAL27 cells. *P < .05, **P < .01, ***P < .001 (4Fg-h) Synthetic therapy reduced the activation of Notch1 and EGFR pathway. Scale bar = 50 μm. *P < .05, **P < .01, ***P < .001
| Dual-pathway inhibition had synergistic inhibitory effects on the PI3K/AKT pathway
with tyrosine kinase activity. 36 The binding of a ligand to the EGFR triggers EGFR autophosphorylation and downstream signalling transduction cascades, including MAPK, STAT3 and PI3K/AKT pathways.
Erlotinib is an intracellular tyrosine kinase enzymatic inhibitor (TKI) that disrupts kinase activity by binding to the adenosine triphosphate (ATP) pocket to interdict EGFR pathway activation.
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We Then, we treated HNSCC with both inhibitors at optimal concentrations. Cell proliferation and invasion were both reduced compared with single treatment in all 5 HNSCC cell lines. Furthermore, cell death was observed in a certain period in vivo and in vitro. This was the first time that we added PF-03084014 in HNSCC and discovered a synthetic lethal relationship between EGFR and Notch1 inhibition in vivo and in vitro.
The crosstalk between the Notch1 and EGFR signalling has been previously described in genetic model systems, where these pathways can function in either an antagonistic or synergistic fashion. 41 However, the mechanism through which this interplay occurs remains unknown. 42 In Active Notch1 pathway is associated with increased cancer progression, and NICD regulates the steps involved in cell metastasis in OSCC. 44 In our recent study about Notch1 pathway, an oncogenic phenotype of NICD in HNSCCs was discovered (data not published).
As demonstrated in this article, upon treatment with Erlotinib alone, increased cell invasion was discovered. Recently, Arasada et al. 13 have
reported that Erlotinib enhances the enrichment of ALDH + stem-like cells through EGFR-dependent activation of Notch3. They demonstrate that inhibition of EGFR kinase activity leads to activation of F I G U R E 5 Dual-pathway inhibition had synergistic inhibitory effects on the PI3K/AKT pathway. (A-B) PI3K/AKT signalling activities were evaluated by Western blot analysis in HN6 and CAL27 cells. Except that EGFR and AKT levels remained unchanged, Erlotinib and PF-03084014 decreased the expression levels of p-EGFR, respectively. PF-03084014 alone activated p-AKT. Synthetic inhibitory effects were observed in p-EGFR, p-AKT and PI3K protein levels. Er 0.1 μM, PF 30 μM. *P < .05, **P < .01, ***P < .001
Notch transcriptional targets in a γ-secretase inhibitor-sensitive manner and causes Notch activation. We established a preclinical therapeutic drug trial in vivo using a Xenograft tumour model of in mice.
By using immumohistochemical staining, the NICD level was upregulated in the group with Erlotinib alone as compared with that in the group with DMSO or PF-03084014. Moreover, combined treatment reversed the activation of NICD. We assumed that the enhanced invasive ability in Transwell assays was due to the upregulation of NICD caused by Erlotinib treatment alone. Efstathia Giannopoulou et al.
have indicated that Notch1 expression is dependent on EGFR protein levels and mutations. 45 In HN6 cells with strong EGFR expression, the invasive ability induced by Erlotinib was relatively increased compared with CAL27. After inhibition of EGFR pathway, cells gained a compensation of Notch1 pathway activation to maintain the viability.
One implication in this experiment was the effect of PF-03084014 on HNSCC. We discovered an enhancement of proliferative and invasive ability in HN6 and CAL27 cells, which has not been described before. Although NICD expression could be inhibited by PF-03084014 at 5 μM, the oncogenic property was still observed in cells treated with 5-20 μM inhibitor. However, UMSCC38
did not show an obvious proliferative increase as PF-03084014
added. We speculated that this enhancement was attributed to PI3K/AKT pathway. PI3K/AKT signalling components are frequently altered in human cancers. 46 The PI3K-AKT signalling pathway reg- 
